Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CET

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
01/17 AMGEN : deCODE Study Shows that Variants in the Sequence of the Genome that Cont..
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/10 AMGEN : Study Results Published in the Journal of the American Medical Associati..
01/10 E THERAPEUTICS : Firm's new chief Drug discovery
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/10 AMGEN : Statement on January 9, 2017, U.S. District Court Decision
01/09 AMGEN, INC. : Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regen..
01/09 AMGEN INC. (NASDAQ : AMGN) Files An 8-K Entry into a Material Definitive Agreeme..
01/09 AMGEN INC : Entry into a Material Definitive Agreement, Termination of a Materia..
More news
Sector news : Bio Therapeutic Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
01/06DJSanofi Investors Count Cost of Praluent Ruling -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/20 Why Gilead Is Undervalued
01/20 FDA Baits Biosimilar Makers With Switching Guidance
01/20 THE MNM PORTFOLIO, DECEMBER 2016 : Ep. 22 - Closing Out A Strong 2016
01/20 Morgan Stanley's 12 Conviction Ideas ahead of earnings
01/19 ONE STEP CLOSER TO FINANCIAL FREEDOM : My 2016 Income Review
Advertisement
Financials ($)
Sales 2016 22 776 M
EBIT 2016 11 096 M
Net income 2016 7 776 M
Debt 2016 2 669 M
Yield 2016 2,53%
P/E ratio 2016 15,07
P/E ratio 2017 14,35
EV / Sales 2016 5,17x
EV / Sales 2017 4,92x
Capitalization 115 062 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 182 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
VERTEX PHARMACEUTICALS..10.45%20 182
More Results